GlassScriptPhysician profile
Corinne Onigbinde
NPI 1396253043
$1,622.68
in general payments reported to CMS, 2019-2025
11 companies · $582 in 2025
The $582 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2022: $337 · 2023: $241 · 2024: $340 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,163.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $453.52 | 2022-2024 | Airsupra |
| Pulmonx Corporation | $147.06 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Corium, LLC | $125.86 | 2023 | Azstarys |
| Abiomed | $121.48 | 2025 | |
| Astellas Pharma US INC | $119.79 | 2021-2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $115.25 | 2024 | Xifaxan |
| Pharmacosmos Therapeutics INC. | $115.24 | 2023 | Monoferric |
| Lilly USA, LLC | $113.36 | 2025 | Mounjaro |
| Pfizer INC. | $111.79 | 2025 | |
| Novo Nordisk INC | $110.53 | 2021 | |
| Abbvie INC. | $88.80 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corinne Onigbinde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.